Characterization of broad-spectrum Mycobacterium abscessus class A -lactamase | Zendy

Daria Soroka | Zendy; Vincent Dubée | Zendy; O. Soulier-Escrihuela | Zendy; Guillaume Cuinet | Zendy; JeanEmmanuel Hugonnet | Zendy; Ludwig Gutmann | Zendy; JeanLuc Mainardi | Zendy; Michel Arthur | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Characterization of broad-spectrum Mycobacterium abscessus class A -lactamase

Author(s) -

Daria Soroka,

Vincent Dubée,

O. Soulier-Escrihuela,

Guillaume Cuinet,

JeanEmmanuel Hugonnet,

Ludwig Gutmann,

JeanLuc Mainardi,

Michel Arthur

Publication year - 2013

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt410

Subject(s) - cefoxitin , mycobacterium abscessus , imipenem , microbiology and biotechnology , moxalactam , sulbactam , chemistry , escherichia coli , mycobacterium , biology , cephalosporin , antibiotics , biochemistry , antibiotic resistance , bacteria , staphylococcus aureus , gene , genetics

Imipenem and cefoxitin are used to treat Mycobacterium abscessus infections and have moderate activity against this fast-growing mycobacterium (MIC₅₀ of 16 and 32 mg/L, respectively). M. abscessus is highly resistant to most other β-lactams, although the underlying mechanisms have not been explored. Here, we characterized M. abscessus class A β-lactamase (Bla(Mab)) and investigated its role in β-lactam resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research